Articles tagged with: MLN9708

News»

[ by and | Dec 11, 2013 6:20 pm | Comments Off ]
ASH 2013 Multiple Myeloma Update – Day Three: Afternoon Oral Sessions

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH).  The day was filled with oral presentation sessions from early in the morning until into the evening.

In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon.  The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.

This ASH update highlights most of …

Read the full story »

News»

[ by | Dec 8, 2013 5:16 pm | 4 Comments ]
ASH 2013 Multiple Myeloma Update – Day One

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.

During the session, research results were made available for review by meeting attendees in …

Read the full story »

News»

[ by | Nov 20, 2013 8:53 pm | 3 Comments ]
ASH 2013 Preview: Treatments In Mid- To Late-Stage Clinical Development For Multiple Myeloma

The Beacon continues today with its ‘ASH preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available, although many contain pre­lim­i­nary information that will be updated at the meet­ing.

The Beacon’s ASH preview articles are intended to highlight the meet­ing’s most interesting myeloma-related studies.

The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest potential mye­lo­ma therapies just starting out in clinical trials.  Further …

Read the full story »

News»

[ by | Updated: Jun 21, 2013 2:30 pm | 4 Comments ]
A Look At The Myeloma-Related Poster Presentations At The EHA Congress (EHA 2013)

This year’s Congress of the European Hematology Association (EHA) is cur­rent­ly being held in Stockholm. It started earlier this week and will run through Sunday, June 16.

A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster pre­sen­ta­tions.

This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and to­mor­row. A previous article covered the key findings that will be pre­sented during oral pre­sen­ta­tions.

The studies covered in this article are …

Read the full story »

News»

[ by and | Jun 11, 2013 5:47 pm | 5 Comments ]
ASCO 2013 And Multiple Myeloma: What Were The Highlights?

This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.

During the meeting, The Beacon published daily updates that provided over­views of the important multiple myeloma findings presented during the meeting.

Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate im­pli­ca­­tions for the treatment of multiple myeloma?  Did the research at the meeting represent a major step for­ward for myeloma …

Read the full story »